Hofseth BioCare margins jump despite revenue fall

Hofseth BioCare reported Q2 2025 revenues of NOK 68.4 million, down from NOK 80.4 million year-over-year, but gross margins expanded significantly to 46% from 34%. Operational EBITDA turned positive at NOK 1.3 million versus negative NOK 2.5 million previously.

Human nutrition B2B sales surged 180% to NOK 9.3 million, driven by demand across Europe, China, and Southeast Asia. The company launched OmeGo Full Spectrum Omegas globally and its ProGo product won awards for healthy aging benefits.